ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Predictive Value and Correlation Study of HOMA2 IR-CP and TyG-BMI for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: To investigate the associations of C-peptide-based insulin resistance index (HOMA2 IR-CP) and triglyceride-glucose-body mass index (TyG-BMI) with metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM), identify independent risk factors for MASLD, construct a clinical predictive model, and evaluate its predictive performance. Methods: A total of 311 T2DM patients were enrolled and randomly assigned to a derivation cohort (218 cases) and a validation cohort (93 cases) at a 7:3 ratio. Predictive factors were screened via LASSO regression, with results integrated with those from logistic regression analysis. A nomogram was developed, and model performance was assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Restricted cubic spline (RCS) regression was used to explore dose-response relationships, and stratified analyses and interaction analyses were performed. Results: HOMA2 IR-CP and TyG-BMI as independent risk factors for MASLD in T2DM patients. The area under the curve (AUC) was 0.805 in the derivation cohort and 0.730 in the validation cohort. Calibration curves showed good agreement between predicted probabilities and actual outcomes, and DCA verified the model's substantial clinical net benefit. RCS analysis revealed a non-linear association between HOMA2 IR-CP and MASLD (P for non-linearity < 0.05), whereas TyG-BMI exhibited a linear association with MASLD (P for non-linearity = 0.139). No significant interaction effects were observed across subgroups stratified by gender, age, BMI, or HbA1c level; however, the associations were more prominent in patients with BMI < 28 kg/m Conclusion: HOMA2 IR-CP and TyG-BMI are independent risk factors for MASLD in T2DM patients. The nomogram model constructed based on these two factors exhibits good predictive performance and can provide a reference for MASLD risk assessment in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.